To assess whether TRAIL–CDK9i would also be effective at killing cells resistant to sorafenib, a targeted therapeutic which is employed as first-line treatment of hepatocellular carcinoma (HCC), we next derived sorafenib-resistant Huh7 HCC cells (Supplementary Fig. 4b). Here, TNFSF10 is linked to hepatocellular carcinoma.